VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
Follow VTGN
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
(10.26) | (14.35) | (24.59) | (20.77) | (17.93) | (47.76) | (59.25) | (29.36) | (51.42) | (69.68) |
Depreciation & Amortization |
0.14 | 0.08 | 0.21 | 0.12 | 0.12 | 0.15 | 0.13 | 0.13 | (0.24) | (0.34) |
Non Cash Items (Other) |
3.53 | 4.53 | 8.13 | 4.81 | 2.35 | 3.59 | 6.94 | 2.13 | 4.19 | 3.97 |
Accounts Receivable Change |
— | — | (0.30) | 0.30 | — | — | — | — | — | — |
Change in payables and accrued liability |
(0.45) | 0.54 | 1.34 | (0.39) | 0.05 | 1.69 | (0.93) | 0.52 | 5.68 | 0.83 |
Change in other assets and liabilities |
(0.23) | 0.13 | 0.68 | 0.18 | 3.34 | (2.93) | 3.39 | 0.77 | (0.31) | (1.20) |
Operating Cash Flow |
(7.26) | (9.06) | (14.53) | (15.76) | (12.07) | (45.26) | (49.72) | (25.81) | (42.10) | (66.44) |
Capital expenditures |
(0.24) | 0.00 | (0.17) | — | (0.28) | (0.20) | (0.21) | (0.06) | (0.19) | (0.15) |
Net Aquisitions |
— | — | — | — | — | — | (0.53) | — | — | — |
Short Term Investments Change (Net) |
— | — | — | — | — | — | — | — | (12.96) | (0.73) |
Investing cash flow |
(0.24) | 0.00 | (0.17) | — | (0.28) | (0.20) | (0.74) | (0.06) | (13.15) | (0.88) |
Repayment/Issuance of Debt (Net) |
(0.18) | (0.21) | (0.22) | 0.00 | (0.38) | 0.00 | (1.03) | (0.98) | — | 0.10 |
Equity Repurchase (Common, Net) |
9.90 | 16.72 | 17.65 | 4.01 | 20.81 | 10.49 | (0.01) | 35.93 | 3.21 | 30.88 |
Equity Repurchase (Preffered, Net) |
0.28 | — | — | — | 93.68 | — | — | — | — | — |
Other financial activities |
3.62 | 4.53 | 8.25 | 4.75 | 2.31 | 3.71 | 6.97 | 93.45 | — | — |
Financing cash flow |
9.99 | 16.52 | 17.42 | 4.01 | 114.10 | 10.48 | (1.04) | 128.40 | 3.21 | 30.97 |
Change in Cash |
2.49 | 7.46 | 2.72 | (11.75) | 101.75 | (34.97) | (51.50) | 102.53 | (52.03) | (36.34) |
Beginning Cash |
0.43 | 2.92 | 10.38 | 13.10 | 1.36 | 103.11 | 68.14 | 16.64 | 119.17 | 67.13 |
Ending Cash |
2.92 | 10.38 | 13.10 | 1.36 | 103.11 | 68.14 | 16.64 | 119.17 | 67.13 | 30.79 |
Stock Based Compensation |
3.11 | 3.96 | 8.08 | 3.91 | 2.31 | 3.48 | 3.34 | 2.18 | 4.32 | 4.00 |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash/Marketcap |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
(0.68) | 0.67 | 1.72 | 0.09 | 3.39 | (1.24) | 2.46 | 1.29 | 5.37 | (0.38) |
Investments Change (Net) |
— | — | — | — | — | — | — | — | (12.96) | (0.73) |
Issuance/Purchase of Shares |
10.18 | 16.72 | 17.65 | 4.01 | 114.48 | 10.49 | (0.01) | 35.93 | 3.21 | 30.88 |
| Other line items | ||||||||||
Revenue per Employee |
0.14 | 0.00 | 0.00 | 0.00 | 0.05 | 0.03 | (0.01) | 0.03 | 0.01 | 0.03 |